Clinical Trials
16 trialsNCT04230109 2026-06-02
NeoSTAR
Massachusetts General Hospital
Phase 2 Recruiting
NCT06963905 2026-05-22
SIMONE
Yale University
Phase 1/2 Recruiting
NCT07011654 2026-05-20
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03606967 2026-05-13
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04434040 2026-05-04
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05633654 2026-04-30
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
Phase 3 Recruiting
NCT04468061 2026-04-29
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07533123 2026-04-16
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
NCT06926920 2026-01-30
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Gilead Sciences
Phase 1/2 Recruiting
NCT06238921 2025-12-05
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06081244 2025-11-19
ADAPT-TN-III
West German Study Group
Phase 3 Recruiting
NCT07046455 2025-07-01
Trop-2 Targeted PET Probes in Advanced TNBC
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT05552001 2025-06-11
ISIdE
UNICANCER
Phase 3 Recruiting
NCT06991790 2025-05-28
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
Peking University Cancer Hospital & Institute
Recruiting
NCT05770531 2025-04-04
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting